General
Preferred name
Galidesivir
Synonyms
BCX 4430 ()
BCX 4430 (hydrochloride) ()
BCX4430 ()
Immucillin-A ()
Galidesivir dihydrochloride ()
Galidesivir (hydrochloride) ()
BCX4430 (hydrochloride) ()
Immucillin-A (hydrochloride) ()
BCX4430 freebase ()
BCX 4430 hydrochloride ()
IMMUCILLIN A ()
BCX-4430 ()
P&D ID
PD043773
CAS
1373208-51-5
249503-25-1
222631-44-9
Tags
available
prodrug
drug candidate
Drug indication
Severe acute respiratory syndrome (SARS)
Middle East Respiratory Syndrome (MERS)
Marburg hemorrhagic fever
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Galidesivir (BCX4430) is an adenosine analogue and broad-spectrum antiviral agent . It was originally developed as a treatment for hepatitis C infection, but has subsequently demonstrated activity against Ebola, Marburg and Zika viruses, and was most recently evaluated for potential to treat SARS-CoV-2 infection (COVID-19). Mechanistically it inhibits the virus' RNA-dependent RNA-polymerase (RdRp), that acts as a nonobligate RNA chain terminator.
(GtoPdb)
PRICE
28
DESCRIPTION
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 ¦ÌM[1][2][3].
DESCRIPTION
BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. BCX4430 may be suitable for administration by intravenous (IV), intramuscular (IM), and oral (PO) routes.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Galidesivir (BCX4430) is a broad-spectrum antiviral compound, an adenosine analog that inhibits viral RNA-dependent RNA polymerase (RdRp) activity.Galidesivir inhibits a wide range of RNA viral pathogens in vitro, and reduces lung infections in infected animals.
(TargetMol Bioactive Compound Library)
DESCRIPTION
BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. BCX4430 may be suitable for administration by intravenous (IV), intramuscular (IM), and oral (PO) routes.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Coronavirus Mpro inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
13
Compound Sets
10
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
ReFrame library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
265.12
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
6
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-1.73
TPSA
140.31
Fraction CSP3
0.45
Chiral centers
4.0
Largest ring
6.0
QED
0.38
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Antiviral
RNA polymerase
DNA/RNA Synthesis
Filovirus
SARS-CoV
Primary Target
RNA Polymerase
MOA
Inhibitor
Therapeutic Class
Antiviral Agents
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Immunology/Inflammation
Anti-infection
Cell Cycle/DNA Damage
Solubility
In Vitro:<br/>H2O : 1.53 mg/mL(5.77 mM
Need ultrasonic and warming)
In Vitro:<br/>DMSO : 105 mg/mL(347.99 mM
Need ultrasonic)<br/>H2O : ≥ 41 mg/mL(135.88 mM)<br/>In Vivo:<br/>1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline<br/>Solubility: ≥ 5.25 mg/mL (17.40 mM)
Clear solution<br/>2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline)<br/>Solubility: ≥ 5.25 mg/mL (17.40 mM)
Clear solution
Source data
